Proatherogenic sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside
| Author | Mezentsev, Alexandre |
| Author | Bezsonov, Evgeny |
| Author | Kashirskikh, Dmitry |
| Author | Baig, Mirza S. |
| Author | Eid, Ali H. |
| Author | Orekhov, Alexander |
| Available date | 2023-07-31T11:37:21Z |
| Publication Date | 2021-05-25 |
| Publication Name | Biomedicines |
| Identifier | http://dx.doi.org/10.3390/biomedicines9060600 |
| Citation | Mezentsev, A., Bezsonov, E., Kashirskikh, D., Baig, M. S., Eid, A. H., & Orekhov, A. (2021). Proatherogenic sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside. Biomedicines, 9(6), 600. |
| Abstract | This review summarizes the main achievements in basic and clinical research of atheroscle-rosis. Focusing on desialylation as the first and the most important reaction of proatherogenic pathological cascade, we speak of how desialylation increases the atherogenic properties of low density lipoproteins and decreases the anti-atherogenic properties of high density lipoproteins. The separate sections of this paper are devoted to immunogenicity of lipoproteins, the enzymes contribut-ing to their desialylation and animal models of atherosclerosis. In addition, we evaluate the available experimental and diagnostic protocols that can be used to develop new therapeutic approaches for atherosclerosis. |
| Sponsor | This research was funded by the Russian Science Foundation, grant number 18-15-00254. |
| Language | en |
| Publisher | Multidisciplinary Digital Publishing Institute (MDPI) |
| Subject | Animal models of atherosclerosis Anti-LDL antibodies Apolipoproteins Atherogenesis Desialylation Diagnostics of atherosclerosis HDL LDL Sialidase Trans-sialidase Treatment options for atherosclerosis |
| Type | Article |
| Issue Number | 6 |
| Volume Number | 9 |
| ESSN | 2227-9059 |
Files in this item
This item appears in the following Collection(s)
-
Medicine Research [1337 items ]